

USA, SEER 18, Hispanic White (1993-2012)

	Age group	Males	Females
Person-years	0	2 763 114	2 652 627
	1-4	10 545 237	10 107 630
	5-9	12 227 194	11 731 674
	10-14	11 909 662	11 391 554
	15-19	11 788 020	10 751 287
Total	0-14	37 445 207	35 883 485
	0-19	49 233 227	46 634 772
Average annual population	0-14	1 872 260	1 794 174
	0-19	2 461 661	2 331 739

Please consult the quality indicators for the constituent registries

USA, SEER 18, Hispanic White (1993-2012)

Registry	Period	Cases	%	Person-years	%
Alaska Natives	-	-	-	-	-
California, Greater California	2000-2012	5785	34.5	32 323 317	33.7
California, Los Angeles	1993-2012	5281	31.5	30 829 468	32.2
California, San Francisco	1993-2012	832	5.0	4 777 473	5.0
California, San José	1993-2012	952	5.7	4 963 347	5.2
Connecticut	1993-2012	472	2.8	2 368 034	2.5
Georgia, Atlanta	1993-2012	287	1.7	1 708 638	1.8
Georgia, Greater Georgia	2000-2012	251	1.5	1 584 890	1.7
Georgia, Rural	1993-2012	0	0.0	16 264	0.0
Hawaii	1993-2012	24	0.1	202 520	0.2
Iowa	1993-2012	144	0.9	820 481	0.9
Kentucky	2000-2012	74	0.4	467 922	0.5
Louisiana	2000-2012	100	0.6	533 838	0.6
Michigan, Detroit	1993-2012	163	1.0	887 738	0.9
New Jersey	2000-2012	937	5.6	5 066 015	5.3
New Mexico	1993-2012	778	4.6	5 561 045	5.8
Utah	1993-2012	367	2.2	1 931 818	2.0
Washington, Seattle	1993-2012	303	1.8	1 825 191	1.9
USA	1993-2012	16750	100.0	95 867 999	100.0

Please consult the quality indicators for the constituent registries

America, North

Georgia, Greater Georgia, Hispanic White
(2000-2012)Iowa, Hispanic White
(1993-2012)Michigan, Detroit, Hispanic White
(1993-2012)

	0-14			0-19			0-14			0-19			0-14			0-19		
	Cases	M/F	ASR	Cases	M/F	ASR	Cases	M/F	ASR	Cases	M/F	ASR	Cases	M/F	ASR	Cases	M/F	ASR
I LEUKAEMIA	74	0.8	58.1	86	0.9	53.2	39	1.8	60.7	45	1.4	54.7	38	1.9	55.3	45	2.2	51.0
a. Lymphoid	59	1.0	46.1	65	1.1	39.8	31	1.8	48.2	34	1.6	41.2	27	1.5	39.0	31	1.6	34.9
b. Acute myeloid	8	0.6	6.4	13	0.4	8.4	6	1.0	9.4	8	0.6	9.8	7	2.5	10.3	10	4.0	11.5
c. CMD	4	0.3	3.2	4	0.3	2.5	0	.	.	1	0.0	1.3	1	.	1.5	1	.	1.2
d. MDS & other	1	0.0	0.8	1	0.0	0.6	1	.	1.6	1	.	1.2	0	.	.	0	.	.
e. Unspecified	2	0.0	1.6	3	0.5	1.9	1	.	1.6	1	.	1.2	3	.	4.5	3	.	3.5
II LYMPHOMA & RELATED	20	1.5	16.1	31	1.2	20.0	10	2.3	15.5	14	1.8	17.1	15	2.8	21.4	22	2.1	24.8
a. Hodgkin	8	3.0	6.6	19	1.4	12.6	5	1.5	7.8	7	1.3	8.6	6	5.0	8.5	11	2.7	12.4
b. Non-Hodgkin except BL	8	1.0	6.4	8	1.0	4.9	2	.	3.1	4	3.0	4.9	3	2.0	4.3	4	3.0	4.5
c. Burkitt (BL)	2	1.0	1.6	2	1.0	1.2	1	0.0	1.5	1	0.0	1.2	2	1.0	2.8	2	1.0	2.2
d. Lymphoreticular	2	1.0	1.6	2	1.0	1.3	2	.	3.1	2	.	2.4	1	.	1.5	2	1.0	2.3
e. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.	3	2.0	4.3	3	2.0	3.3
III CNS NEOPLASMS	31	1.8	24.6	36	2.0	22.5	30	2.0	46.5	33	2.0	39.9	24	1.4	35.0	26	1.4	29.5
a. Ependymoma	4	0.3	3.1	4	0.3	2.4	4	3.0	6.3	4	3.0	4.9	2	1.0	2.9	2	1.0	2.3
b. Astrocytoma	10	1.0	8.0	15	1.5	9.6	14	1.8	21.8	15	1.5	18.1	9	0.8	13.2	10	1.0	11.4
c. CNS embryonal	8	.	6.3	8	.	4.9	5	0.7	7.7	7	1.3	8.5	7	1.3	10.4	8	1.0	9.2
d. Other gliomas	7	1.3	5.6	7	1.3	4.3	5	4.0	7.7	5	4.0	6.0	5	4.0	7.1	5	4.0	5.5
e. Other specified	0	.	.	0	.	.	2	.	3.1	2	.	2.4	0	.	.	0	.	.
f. Unspecified CNS	2	.	1.7	2	.	1.3	0	.	.	0	.	.	1	.	1.4	1	.	1.1
IV NEUROBLASTOMA	8	1.0	6.1	8	1.0	4.7	5	4.0	7.8	5	4.0	6.1	15	0.4	21.9	15	0.4	17.0
a. (Ganglio)neuroblastoma	8	1.0	6.1	8	1.0	4.7	5	4.0	7.8	5	4.0	6.1	15	0.4	21.9	15	0.4	17.0
b. Peripheral nervous	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
V RETINOBLASTOMA	10	1.5	7.6	10	1.5	5.9	5	0.3	7.8	5	0.3	6.1	6	.	9.0	6	.	7.0
VI RENAL TUMOURS	14	0.6	10.7	14	0.6	8.3	3	0.0	4.7	3	0.0	3.6	7	1.3	10.3	7	1.3	8.0
a. Nephroblastoma	14	0.6	10.7	14	0.6	8.3	3	0.0	4.7	3	0.0	3.6	7	1.3	10.3	7	1.3	8.0
b. Renal carcinoma	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
c. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
VII HEPATIC TUMOURS	2	0.0	1.5	3	0.0	1.9	4	3.0	6.2	4	3.0	4.8	1	.	1.5	1	.	1.2
a. Hepatoblastoma	2	0.0	1.5	2	0.0	1.2	4	3.0	6.2	4	3.0	4.8	1	.	1.5	1	.	1.2
b. Hepatic carcinoma	0	.	.	1	0.0	0.7	0	.	.	0	.	.	0	.	.	0	.	.
c. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
VIII BONE TUMOURS	9	1.3	7.4	15	2.0	9.8	3	2.0	4.6	3	2.0	3.6	2	1.0	2.8	5	4.0	5.7
a. Osteosarcoma	6	2.0	5.0	7	2.5	4.5	1	.	1.5	1	.	1.2	2	1.0	2.8	4	3.0	4.5
b. Chondrosarcoma	0	.	.	1	.	0.7	0	.	.	0	.	.	0	.	.	0	.	.
c. Ewing & related	3	0.5	2.4	7	1.3	4.6	2	1.0	3.1	2	1.0	2.4	0	.	.	1	.	1.2
d. Other specified	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
e. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
IX SOFT TISSUE SARCOMA	12	0.5	9.7	15	0.7	9.5	5	0.3	7.8	6	0.2	7.3	5	0.3	7.2	8	0.3	9.1
a. Rhabdomyosarcoma	5	0.0	4.0	7	0.2	4.5	2	1.0	3.1	2	1.0	2.4	1	0.0	1.4	1	0.0	1.1
b. Fibrosarcoma	2	.	1.6	2	.	1.2	0	.	.	0	.	.	1	0.0	1.4	1	0.0	1.1
c. Kaposi sarcoma	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
d. Other specified	2	1.0	1.7	3	2.0	2.0	2	0.0	3.1	3	0.0	3.7	3	0.5	4.4	5	0.3	5.7
e. Unspecified	3	0.5	2.4	3	0.5	1.8	1	0.0	1.6	1	0.0	1.2	0	.	.	1	.	1.2
X GERM CELL TUMOURS	5	1.5	4.0	18	3.5	11.9	10	0.7	15.7	17	1.4	21.1	4	1.0	5.8	12	2.0	13.9
a. CNS germ cell	2	1.0	1.6	3	0.5	1.9	1	.	1.6	2	.	2.5	1	.	1.4	2	.	2.3
b. Other extragonadal	0	.	.	1	.	0.7	1	.	1.6	2	.	2.5	1	0.0	1.5	2	0.0	2.3
c. Gonadal germ cell	3	2.0	2.4	14	6.0	9.3	7	0.4	10.9	12	1.0	14.9	2	1.0	2.9	8	3.0	9.3
d. Gonadal carcinoma	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
e. Unspecified gonadal	0	.	.	0	.	.	1	0.0	1.6	1	0.0	1.2	0	.	.	0	.	.
XI CARCINOMA & MELANOMA	4	0.3	3.3	14	0.4	9.3	4	1.0	6.3	9	0.3	11.3	6	0.5	8.4	16	0.3	18.2
a. Adrenocortical	0	.	.	0	.	.	1	.	1.6	1	.	1.2	0	.	.	0	.	.
b. Thyroid	3	0.0	2.5	7	0.0	4.6	1	0.0	1.6	4	0.0	5.0	3	0.5	4.2	8	0.3	9.1
c. Nasopharyngeal	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
d. Melanoma	0	.	.	3	2.0	2.0	1	0.0	1.6	1	0.0	1.2	2	1.0	2.8	4	1.0	4.5
e. Skin carcinoma	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
f. Other & unspecified	1	.	0.8	4	1.0	2.7	1	.	1.6	3	0.5	3.8	1	0.0	1.4	4	0.0	4.6
XII OTHER & UNSPECIFIED	0	.	.	1	0.0	0.7	0	.	.	0	.	.	0	.	.	0	.	.
a. Other specified	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
b. Other unspecified	0	.	.	1	0.0	0.7	0	.	.	0	.	.	0	.	.	0	.	.
TOTAL	189	1.0	149.1	251	1.1	157.7	118	1.4	183.6	144	1.3	175.4	123	1.4	178.8	163	1.4	185.3

Please consult the quality indicators for the constituent registries